Compare Cenovus Energy Inc (CVE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs GeneDx Holdings Corp — how do they compare? Cenovus Energy Inc trades at $31.36 (market cap $57.90B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Cenovus Energy Inc is far larger — about 28.7× GeneDx Holdings Corp's market cap, and Cenovus Energy Inc pays a 1.97% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and GeneDx Holdings Corp for 19 Days on average.
| CVE | WGS | |
|---|---|---|
Market Cap | $57.90B | $2.02B |
Volume | 7,863,588 | 734,640 |
Sector | Energy | Health |
52-Week High | $33.92 | $167.51 |
52-Week Low | $15.85 | $34.51 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | $63.84B | $2.05B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.39, up 2.48% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, ROE of 20.96%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight growing optimism around the company's growth prospects and attractive valuation metrics.
CVE presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors should monitor energy price volatility and execution risks. The company's improving cash flow outlook and shareholder returns through dividends provide additional support for long-term value creation.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
